Abstract

In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk, we collected, laboratory test results, blood pressure, demographic, cognitive, motor, olfactory and affective information enabling the assessment of each component of MS and the construction of the MDS prodromal probability score. The number of metabolic components and their levels were compared between participants who were separated based on disease state and genetic status. One hundred and four idiopathic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated in this study. PD groups and non manifesting carriers (NMC) did not differ in the number of metabolic components (p = 0.101, p = 0.685, respectively). LRRK2-PD had higher levels of triglycerides (p = 0.015) and higher rates of prediabetes (p = 0.004), while LRRK2-NMC had higher triglyceride levels (p = 0.014). NMC with probability rates for prodromal PD above 50% had higher frequencies of hypertriglyceridemia and prediabetes (p < 0.005, p = 0.023 respectively). While elevated triglycerides and prediabetes were more frequent among LRRK2 carriers, MS does not seem to influence GBA and LRRK2-PD phenotype.

Details

Title
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
Author
Thaler Avner 1 ; Shenhar-Tsarfaty Shani 2 ; Shaked Yanay 3 ; Gurevich, Tanya 1 ; Omer Nurit 4 ; Bar-Shira Anat 5 ; Gana-Weisz Mali 6 ; Goldstein, Orly 6 ; Kestenbaum Meir 7 ; Cedarbaum, Jesse M 8 ; Orr-Urtreger Avi 9 ; Giladi Nir 1 ; Mirelman Anat 10 

 Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Department of Internal Medicine “C”, “D”, and “E”, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922) 
 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Genetic Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922) 
 Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922) 
 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Neurology department, Meir Hospital, Kfar-Saba, Israel (GRID:grid.415250.7) (ISNI:0000 0001 0325 0791) 
 Biogen Inc, Cambridge, USA (GRID:grid.417832.b) (ISNI:0000 0004 0384 8146); Coeruleus Clinical Sciences LLC, Woodbridge, USA (GRID:grid.417832.b) 
 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922) 
10  Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2411080585
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.